AC Immune (NASDAQ:ACIU) Announces Quarterly Earnings Results

AC Immune (NASDAQ:ACIU) announced its quarterly earnings data on Wednesday. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.09), FiscalAI reports. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. The firm had revenue of $18.67 million during the quarter, compared to the consensus estimate of $34.08 million.

AC Immune Stock Performance

Shares of AC Immune stock traded up $0.04 during trading on Wednesday, hitting $2.31. 100,419 shares of the stock were exchanged, compared to its average volume of 291,459. The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The company has a fifty day moving average price of $2.39 and a 200-day moving average price of $2.79. The stock has a market capitalization of $234.58 million, a price-to-earnings ratio of -2.81 and a beta of 1.59. AC Immune has a 1-year low of $2.03 and a 1-year high of $4.00.

Insider Buying and Selling

In other AC Immune news, CEO Andrea Pfeifer sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the transaction, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. EFG International AG bought a new stake in AC Immune in the 4th quarter valued at $41,000. Private Advisor Group LLC bought a new position in shares of AC Immune in the third quarter valued at about $48,000. Goldman Sachs Group Inc. boosted its holdings in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after buying an additional 5,920 shares during the period. Susquehanna International Group LLP acquired a new position in AC Immune in the 3rd quarter valued at about $63,000. Finally, Sei Investments Co. bought a new position in AC Immune in the 2nd quarter valued at about $51,000. 51.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ACIU. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a research report on Wednesday, July 1st. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Monday, May 4th. Finally, Weiss Ratings downgraded AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.50.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.